136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial

M. J. Ahn; J. Yang; H. Yu; H. Saka; S. Ramalingam; K. Goto; S. W. Kim; L. Yang; A. Walding; G. R. Oxnard

doi:10.1016/S1556-0864(16)30246-5

136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial

M. J. Ahn, J. Yang, H. Yu, H. Saka, S. Ramalingam, K. Goto, S. W. Kim, L. Yang, A. Walding, G. R. Oxnard

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	S115
Journal	Journal of Thoracic Oncology
Volume	11
Issue number	4
DOIs	https://doi.org/10.1016/S1556-0864(16)30246-5
Publication status	Published - 04-2016
Externally published	Yes

All Science Journal Classification (ASJC) codes

Oncology
Pulmonary and Respiratory Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S1556-0864(16)30246-5

Cite this

@article{b40238d2b5d540eea805caa8191a84b7,

title = "136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial",

author = "Ahn, {M. J.} and J. Yang and H. Yu and H. Saka and S. Ramalingam and K. Goto and Kim, {S. W.} and L. Yang and A. Walding and Oxnard, {G. R.}",

year = "2016",

month = apr,

doi = "10.1016/S1556-0864(16)30246-5",

language = "English",

volume = "11",

pages = "S115",

journal = "Journal of Thoracic Oncology",

issn = "1556-0864",

publisher = "Elsevier Inc.",

number = "4",

}

TY - JOUR

T1 - 136O

T2 - Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial

AU - Ahn, M. J.

AU - Yang, J.

AU - Yu, H.

AU - Saka, H.

AU - Ramalingam, S.

AU - Goto, K.

AU - Kim, S. W.

AU - Yang, L.

AU - Walding, A.

AU - Oxnard, G. R.

PY - 2016/4

Y1 - 2016/4

UR - http://www.scopus.com/inward/record.url?scp=85040257501&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040257501&partnerID=8YFLogxK

U2 - 10.1016/S1556-0864(16)30246-5

DO - 10.1016/S1556-0864(16)30246-5

M3 - Article

AN - SCOPUS:85040257501

SN - 1556-0864

VL - 11

SP - S115

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

IS - 4

ER -

136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Cite this